<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6648">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997113</url>
  </required_header>
  <id_info>
    <org_study_id>MMRF093051</org_study_id>
    <nct_id>NCT00997113</nct_id>
  </id_info>
  <brief_title>Stress During Deep Sedation With Propofol With and Without Alfentanil</brief_title>
  <official_title>Physiologic Stress During Procedural Sedation With and Without Alfentanil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minneapolis Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minneapolis Medical Research Foundation</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized clinical trial of deep procedural sedation with propofol with and
      without supplemental alfentanil. Patients will be assessed for total and fractionated serum
      catecholamines before and after the procedure in addition to usual procedural sedation
      outcomes parameters to assess the adrenergic effect of propofol sedation without
      supplemental opioid.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Serum Catecholamines</measure>
    <time_frame>one minute prior to the start of the procedure and immediately at the end of sedation procedure (median time of procedure 12 minutes range 6-26 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in serum catecholamine levels, values indicate a decrease over the procedure. These patients underwent fracture reduction procedures which are typically associated with an increase in catecholamines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory Depression</measure>
    <time_frame>From one minute prior to the start of the sedation procedure until the patient has returned to baseline mental status</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>categorized as a change in end tidal CO2 from baseline &gt;10mmhg, a loss of end tidal CO2 waveform for more than 6 seconds, or an oxygen saturation less than 93%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Pain and Recall of the Painful Procedure for Which They Were Sedated Measure by Patient Query After They Had Regained Their Baseline Level of Consciousness After the Procedure</measure>
    <time_frame>single time point measured after sedation procedure completed</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain and recall were measured seperately by direct patient query. The patient was asked if they experienced any pain during the procedure. The patient was then asked if they could recall any part of the fracture reduction. Patients who had either pain with the procedure of recall of the procedure were counted as having pain or recall with the procedure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>propofol only for deep procedural sedation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol/alfentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol with alfentanil for deep procedural sedation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>1 mg/kg IV followed by 0.5 mg/kg iv prn sedation</description>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_label>Propofol/alfentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alfentanil</intervention_name>
    <description>alfentanil 10 ug/kg immediately prior to propofol dose</description>
    <arm_group_label>Propofol/alfentanil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who will require deep procedural sedation with propofol in the ED

        Exclusion Criteria:

          -  age &lt;18

          -  intoxication

          -  unable to provide informed consent

          -  allergy to propofol or alfentanil

          -  pregnant

          -  ASA physical status score &gt; 2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James R. Miner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hennepin Faculty Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Miner JR, Moore JC, Plummer D, Gray RO, Patel S, Ho JD. Randomized clinical trial of the effect of supplemental opioids in procedural sedation with propofol on serum catecholamines. Acad Emerg Med. 2013 Apr;20(4):330-7. doi: 10.1111/acem.12110.</citation>
    <PMID>23701339</PMID>
  </results_reference>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 21, 2014</lastchanged_date>
  <firstreceived_date>October 12, 2009</firstreceived_date>
  <firstreceived_results_date>March 28, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>propofol</keyword>
  <keyword>alfentanil</keyword>
  <keyword>procedural sedation</keyword>
  <keyword>stress biomarkers</keyword>
  <keyword>Deep procedural sedation in the ED</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alfentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>34 patients were elligible, 14 underwent sedation emergently before the patient could be approached for study enrollment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Propofol</title>
          <description>propofol only for deep procedural sedation
propofol: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation</description>
        </group>
        <group group_id="P2">
          <title>Propofol/Alfentanil</title>
          <description>Propofol with alfentanil for deep procedural sedation
propofol: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
alfentanil: alfentanil 10 ug/kg immediately prior to propofol dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Propofol</title>
          <description>propofol only for deep procedural sedation
propofol: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation</description>
        </group>
        <group group_id="B2">
          <title>Propofol/Alfentanil</title>
          <description>Propofol with alfentanil for deep procedural sedation
propofol: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
alfentanil: alfentanil 10 ug/kg immediately prior to propofol dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="34" lower_limit="18" upper_limit="60"/>
                <measurement group_id="B2" value="36" lower_limit="20" upper_limit="58"/>
                <measurement group_id="B3" value="35" lower_limit="18" upper_limit="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Catecholamines</title>
        <description>change in serum catecholamine levels, values indicate a decrease over the procedure. These patients underwent fracture reduction procedures which are typically associated with an increase in catecholamines.</description>
        <time_frame>one minute prior to the start of the procedure and immediately at the end of sedation procedure (median time of procedure 12 minutes range 6-26 minutes</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Propofol</title>
            <description>propofol only for deep procedural sedation
propofol: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation</description>
          </group>
          <group group_id="O2">
            <title>Propofol/Alfentanil</title>
            <description>Propofol with alfentanil for deep procedural sedation
propofol: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
alfentanil: alfentanil 10 ug/kg immediately prior to propofol dose</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Serum Catecholamines</title>
            <description>change in serum catecholamine levels, values indicate a decrease over the procedure. These patients underwent fracture reduction procedures which are typically associated with an increase in catecholamines.</description>
            <units>mcg/ml</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="87" lower_limit="1" upper_limit="353"/>
                  <measurement group_id="O2" value="106" lower_limit="21" upper_limit="295"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the change in serum catecholamines from one minute before the procedure to one minute after. In order to detect a 20% difference in mean catecholamine values between groups, assuming a 30% standard deviation, with an alpha of 0.05 and a beta of 0.2 (80% power), power analysis indicated that 10 patients per group were required.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.940</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Depression</title>
        <description>categorized as a change in end tidal CO2 from baseline &gt;10mmhg, a loss of end tidal CO2 waveform for more than 6 seconds, or an oxygen saturation less than 93%.</description>
        <time_frame>From one minute prior to the start of the sedation procedure until the patient has returned to baseline mental status</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Propofol</title>
            <description>propofol only for deep procedural sedation
propofol: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation</description>
          </group>
          <group group_id="O2">
            <title>Propofol/Alfentanil</title>
            <description>Propofol with alfentanil for deep procedural sedation
propofol: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
alfentanil: alfentanil 10 ug/kg immediately prior to propofol dose</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Respiratory Depression</title>
            <description>categorized as a change in end tidal CO2 from baseline &gt;10mmhg, a loss of end tidal CO2 waveform for more than 6 seconds, or an oxygen saturation less than 93%.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Pain and Recall of the Painful Procedure for Which They Were Sedated Measure by Patient Query After They Had Regained Their Baseline Level of Consciousness After the Procedure</title>
        <description>Pain and recall were measured seperately by direct patient query. The patient was asked if they experienced any pain during the procedure. The patient was then asked if they could recall any part of the fracture reduction. Patients who had either pain with the procedure of recall of the procedure were counted as having pain or recall with the procedure.</description>
        <time_frame>single time point measured after sedation procedure completed</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Propofol</title>
            <description>propofol only for deep procedural sedation
propofol: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation</description>
          </group>
          <group group_id="O2">
            <title>Propofol/Alfentanil</title>
            <description>Propofol with alfentanil for deep procedural sedation
propofol: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
alfentanil: alfentanil 10 ug/kg immediately prior to propofol dose</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patient Reported Pain and Recall of the Painful Procedure for Which They Were Sedated Measure by Patient Query After They Had Regained Their Baseline Level of Consciousness After the Procedure</title>
            <description>Pain and recall were measured seperately by direct patient query. The patient was asked if they experienced any pain during the procedure. The patient was then asked if they could recall any part of the fracture reduction. Patients who had either pain with the procedure of recall of the procedure were counted as having pain or recall with the procedure.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Propofol</title>
          <description>propofol only for deep procedural sedation
propofol: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation</description>
        </group>
        <group group_id="E2">
          <title>Propofol/Alfentanil</title>
          <description>Propofol with alfentanil for deep procedural sedation
propofol: 1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
alfentanil: alfentanil 10 ug/kg immediately prior to propofol dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>apnea</sub_title>
                <description>patient inadvertently given 5 times the study dose of alfentanil, developed apnea that resovled with bag valve mask ventilation over 2 minutes, resolved completely after 2 minutes without subsequent difficulty</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Miner</name_or_title>
      <organization>Minneapolis Medical Reseach Foundation</organization>
      <phone>6128738791</phone>
      <email>miner015@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
